Generation Bio Stock

generationbio.comHealthcareFounded: 2016Funding to Date: $125.37MM

Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases.

Register for Details

For more details on financing and valuation for Generation Bio, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Generation Bio.

Register Today

Team

Management Team

Thomas Graney
Chief Financial Officer
Will McCarthy
Chief Business Officer
Jason Rhodes
Chairman & Co-Founder
Mark Angelino Ph.D
Chief Operating Officer & Co-Founder
Robert Kotin Ph.D
Co-Founder & Head of Discovery
Geoffrey McDonough MD
Chief Executive Officer, President & Board Member
Jennifer Elliott Ph.D
Vice President, Head of Legal Affairs and Intellectual Property

Board Members

Donald Nicholson Ph.D
Anthony Quinn Ph.D
Geoffrey McDonough MD
Gustav Christensen
Jeffrey Jonas MD
Catherine Stehman-Breen MD
Jason Rhodes

Other companies like Generation Bio in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$885.01MM
Sector
 
 

News

JP Morgan’s annual healthcare conference convenes in San Francisco this week and Generation Bio CEO Geoff McDonough is betting gene therapy will be among
Generation Bio, a Cambridge, MA-based gene therapy company, closed a $110m Series C financing. round led by T. Rowe Price funds and accounts
Generation Bio announced that Steven Dowdy, Ph.D., has joined its Scientific Advisory Board.